Global Diagnostics Partnering 2010-2015: Deal Trends, Players, Financials and Forecasts
DUBLIN, Sept. 22, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/9d3gz3/global) has announced the addition of the "Global Diagnostics Partnering 2010-2015: Deal trends, players, financials and forecasts" report to their offering.
The Global Diagnostics Partnering 2010-2015 report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms.
This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:
- Companion Diagnostics
- Imaging
- CT
- Endoscope
- Molecular and nuclear
- MRI
- Ultrasound
- X-ray
- PET
- SPECT
- Angiography
- Fluroscopy
- Mammography
- In vitro diagnostics
- Molecular diagnostics
- Prognostics
- Theranostics
Report scope:
Global Diagnostics Partnering 2010-2015 is intended to provide the reader with an in-depth understanding of the diagnostic trends and structure of deals entered into by leading companies worldwide.
Global Diagnostics Partnering 2010-2015 includes:
- Trends in diagnostic dealmaking in the biopharma industry since 2010
- Analysis of diagnostic deal structure
- Case studies of real-life diagnostic deals
- Access to over 3,000 diagnostic deals
- The leading diagnostic deals by value since 2010
- Most active diagnostic dealmakers since 2010
- The leading diagnostic partnering resources
In Global Diagnostics Partnering 2010-2015 , the available contracts are listed by:
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Companies Mentioned - Partial List
- Abaxis
- Abbott Laboratories
- Accuray
- Achaogen
- Actavis (acquired by Watson)
- Acusphere
- ADMA Biologics
- Aegea Biotechnologies
- Alnylam Pharmaceuticals
- Alseres Pharmaceuticals
- Altair Nanotechnologies
- Amarantus BioSciences
- Ambit Biosciences
- AMDL Diagnostics
- AmpliPhi Biosciences
- Amway Global
- ARK Diagnostics
- Arno Therapeutics
- Arrayit
- Arrayit Diagnostics
- AspenBio Pharma
- Asuragen
- Atossa Genetics
- Audeo Oncology
- Axial Biotech
- Bayer Schering Pharma
- Beckman Coulter
- Beijing C&D
- BG Medicine
- Bio-Imaging Technologies
- Bio-Matrix Scientific
- Biocept
- BioClinica
- Biofield
- Biogen Idec
For more information visit http://www.researchandmarkets.com/research/9d3gz3/global
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
Related Links
http://www.researchandmarkets.com
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article